Studies on the Metabolic Fate of Amrubicin Hydrochloride(SM-5887), a Novel Antitumor Agent (5)-Placental Transfer and Excretion into Milk.
|
Accession number;99A0241101
|
| Title;Studies on the Metabolic Fate of Amrubicin Hydrochloride(SM-5887), a Novel Antitumor Agent (5)-Placental Transfer and Excretion into Milk. |
| Author;
NAKAI SHUNJI
(Sumitomo Chemical Co., Ltd.)
ITO MASAKI
(Sumitomo Chemical Co., Ltd.)
KANAMARU HIROSHI
(Sumitomo Chemical Co., Ltd.)
NAKATSUKA IWAO
(Sumitomo Chemical Co., Ltd.)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.27;NO.Suppl.1;PAGE.S.521-S.530(1999)
|
| Figure&Table&Reference;FIG.3, TBL.3, REF.5 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Placental transfer and excretion into milk of amrubicin hydrochloride(SM-5887), a novel antitumor agent, were studied after single intravenous administrations of 14C-labeled SM-5887 at a dose of 10mg/kg to pregnant and lactating female rats. 1) After administration to pregnant rats on day 12 and 18 of gestation, the radioactivity concentrations in the whole bodies or various tissues of fetuses were similar to or higher than the maternal plasma concentrations. The level of radioactivity distributed into each fetus on day 18 of gestation was 0.17% of the dosed radioactivity. These results suggest that SM-5887 is transferred to the fetuses through the placenta. 2) The radioactivity concentration in the milk showed a maximum at 30min after administration to lactating rats. The level of the radioactivity transferred into the milk between 30min and 4hr after administration was about 3 times as high as that in the maternal plasma. These results suggest that SM-5887 is transferred to the milk. (author abst.) |
|
|
|
Related Articles;
|
|
